Internal Quality Control of PCR-based Genotyping Methods in Research Studies and Patient Diagnostics

Summary

Genetic analyses are increasingly integrated in the clinical laboratory, and internal quality control programmes are needed. We have focused on quality control aspects of selected polymorphism analyses used in thrombosis research. DNA was isolated from EDTA-blood (n = 500) by ammonium acetate precipitation and analysed for 18 polymorphisms by polymerase chain reaction (PCR), i. e. restriction fragment length polymorphisms, allele specific amplification, or amplification of insertion/deletion fragments. We evaluated the following aspects in the analytical procedures: sample handling and DNA-isolation (pre-analytical factors), DNA-amplification, digestion with restriction enzymes, electrophoresis (analytical factors), result reading and entry into a database (post-analytical factors). Furthermore, we evaluated a procedure for result confirmation. Isolated DNA was of good quality (42 µ.g/ml blood, A260/A280 ratio >1.75, negative DNAsis tests), and the reagent blank was contaminated in <1% of the results. Occasionally, results were re-analysed because of positive reagent blanks (<1%) or because of problems with the controls (< 5%). On confirmation, we observed 4 genotyping discrepancies. Control of data handling revealed 0.1% reading mistakes and 0.5% entry mistakes. Based on our experiences we propose an internal quality control programme for widely used PCR-based haemostasis polymorphism analyses.

Keywords

Quality control - DNA-analyses - PCR - polymorphism - haemostasis

• References

• 1 Braun A, Deufel T, Geilenkeuser W-J, Neumaier M, Röhle G, Roscher A, Wagener C. External quality assessment of molecular biology-based methods used in laboratories of clinical chemistry and human genetics. Clin Chem Lab Med 1998; 36: 231-4.
• 2 Neumaier M, Braun A, Gessner R, Funke H. Experiences with external quality assessment (EQA) in molecular diagnostics in clinical laboratories in Germany. Clin Chem Lab Med 2000; 38: 161-3.
• 3 Dequeker E, Ramsden S, Grody WW, Stenzel TT, Barton DE. Quality control in molecular genetic testing. Nat Rev Genet 2001; 02: 717-23.
• 4 Lutz CT, Foster PA, Noll WW, Voelkerding KV, Press RD, McGlennen RC, Kirschbaum NE. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes. Clin Chem 1998; 44: 1356-8.
• 5 Preston FE, Kitchen S, Jennings I, Woods TAL. A UK National Quality Assessment Scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial Thrombophilia. Thromb Haemost 1999; 82: 1556-7.
• 6 McGovern MM, Benach MO, Wallenstein A, Desnick RJ, Keenlyside R. Quality assurance in molecular genetic testing laboratories. JAMA 1999; 281: 835-40.
• 7 Woods TAL, Kitchen S, Preston FE. Quality assessment of haemostatic assays and external quality assessment schemes. In: Jespersen J, Bertina RM, Haverkate F. (eds). Laboratory techniques in thrombosis. A manual. 2nd edn. Dordrecht: Kluwer Academic Publishers; 1999: 29-36.
• 8 Neumaier M, Braun A, Wagener C. Fundamentals of quality assessment of molecular amplification methods in clinical diagnostics. Clin Chem 1998; 44: 12-26.
• 9 Burkardt H-J. Standardization and quality control of PCR analyses. Clin Chem Lab Med 2000; 38: 87-91.
• 10 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
• 11 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 12 Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
• 13 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 14 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
• 15 De Maat MPM, Green F, de Knijff P, Jespersen J, Kluft C. Factor VII polymorphisms in populations with different risks of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 1918-23.
• 16 Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the ß fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-90.
• 17 Carter AM, Catto AJ, Grant PJ. Association of the 1-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-6.
• 18 Van Harmelen V, Wahrenberg H, Eriksson P, Arner P. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue. Thromb Haemost 2000; 83: 304-8.
• 19 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JI, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
• 20 Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary heart disease. Circulation 1997; 95: 2032-6.
• 21 Kleesiek K, Schmidt M, Götting C, Schwenz B, Lange S, Müller-Berghaus G, Brinkmann T, Prohaska W. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
• 22 Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ, MacMahon S. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995; 345: 1600-3.
• 23 Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
• 24 Engel H, Zwang L, van Vliet HHDM, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996; 75: 267-9.
• 25 Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost 1997; 78: 1157-63.
• 26 Ludwig M, Wohn K-D, Schleuning W-D, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 1992; 88: 388-92.
• 27 Evans AE, Poirier O, Kee F, Lecerf L, McCrum E, Falconer T, Crane J, O`Rourke DF, Cambien F. Polymorphisms of the angiotensin-convertingenzyme gene in subjects who die from coronary heart disease. Q J Med 1994; 87: 211-4.
• 28 Odawara M, Matsunuma A, Yamashita K. Mistyping frequency of the angiotensin-converting enzyme gene polymorphism and an improved method for its avoidance. Hum Genet 1997; 100: 163-6.
• 29 Liebman HA, Sutherland D, Bacon R, McGehee W. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: Demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance. Br J Haematol 1996; 95: 550-3.
• 30 Fujimura FK, Northrup H, Beaudet AL, O’Brien WE. Genotyping errors with the polymerase chain reaction. N Engl J Med 1990; 322: 61.